Can Patients Switch from Trulicity® to Mounjaro®?

Why Patients and Clinicians Consider This Switch

Switching from Trulicity to Mounjaro is one of the most common medication transitions in type 2 diabetes and weight-management care today. Dulaglutide, a GLP-1 receptor agonist approved in 2014, is effective, but tirzepatide's dual mechanism frequently delivers substantially better glycemic and weight outcomes for the same once-weekly injection schedule.

The Core Pharmacological Difference

Dulaglutide binds only the GLP-1 receptor, stimulating insulin secretion in a glucose-dependent manner and slowing gastric emptying [1]. Tirzepatide binds both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor with roughly equal affinity [2]. That dual agonism amplifies insulin secretion, suppresses glucagon more completely, and produces stronger satiety signaling through central nervous system pathways distinct from GLP-1 alone [3].

Who Is Most Likely to Benefit from Switching

Patients most likely to benefit include those who:

• Have not reached an A1C target of <7.0% (per 2024 ADA Standards of Care) on dulaglutide 1.5 mg [4]
• Have lost <5% of body weight after 12 or more weeks on a stable dulaglutide dose
• Tolerate GLP-1-class side effects without serious adverse events
• Have commercial or Medicare Part D insurance that covers tirzepatide, or plan to use manufacturer savings programs

Patients Who May Not Be Good Candidates

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not receive either drug, per FDA labeling [5]. Pregnancy, severe gastroparesis, and a history of pancreatitis are relative contraindications to both agents [6].

Head-to-Head Evidence: SURPASS-2 Trial

The most directly relevant trial comparing these two drugs is SURPASS-2, a randomized, open-label, phase 3 study (N=1,879) published in the New England Journal of Medicine in 2021.

Primary Glycemic Outcome

All three tirzepatide doses (5 mg, 10 mg, and 15 mg) produced statistically superior A1C reductions compared with dulaglutide 1.5 mg at 40 weeks [7]:

| Treatment | Mean A1C Reduction | % Reaching A1C <7.0% | |---|---|---| | Tirzepatide 5 mg | 2.01% | 82% | | Tirzepatide 10 mg | 2.24% | 87% | | Tirzepatide 15 mg | 2.58% | 89% | | Dulaglutide 1.5 mg | 1.10% | 61% |

All pairwise comparisons: P<0.001 [7].

Weight Loss Outcomes

Mean body weight change at 40 weeks in SURPASS-2 [7]:

• Tirzepatide 5 mg: minus 7.6 kg
• Tirzepatide 10 mg: minus 9.3 kg
• Tirzepatide 15 mg: minus 11.2 kg (approximately 13.1 kg in the full intention-to-treat analysis reported in supplementary data)
• Dulaglutide 1.5 mg: minus 2.4 kg

The NEJM authors stated: "Tirzepatide was noninferior and superior to dulaglutide with respect to the change in the glycated hemoglobin level, and all doses of tirzepatide resulted in a significantly greater reduction in body weight than dulaglutide." [7]

Cardiovascular and Renal Signal

SURPASS-4 (N=2,002, high cardiovascular risk) showed tirzepatide 15 mg reduced UACR (urinary albumin-to-creatinine ratio) by 24% versus insulin glargine at 52 weeks [8]. Dedicated cardiovascular outcomes data come from the SURPASS-CVOT trial (SURPASS-4 for CV events), which is ongoing, but post-hoc analyses suggest favorable trends [8]. The ADA notes: "For patients with type 2 diabetes and established CVD or high CV risk, a GLP-1 RA with proven cardiovascular benefit should be considered." [4]

How to Switch: A Step-by-Step Clinical Protocol

Switching from dulaglutide to tirzepatide does not require a pharmacological washout period. Dulaglutide has a half-life of approximately 5 days, and both drugs share overlapping receptor activity, so there is no risk of dangerous additive toxicity during transition [9].

Step 1: Time the Last Dulaglutide Dose

Administer the final dulaglutide dose on the patient's normal injection day. Do not add an extra dose. Begin tirzepatide on the following scheduled weekly injection day (7 days later) or, in some clinical protocols, on the same day as the last dulaglutide dose if glycemic urgency exists. Most clinicians prefer the next-week start to allow any residual GI side effects from dulaglutide to clear [10].

Step 2: Start Tirzepatide at 2.5 mg

FDA labeling mandates that all patients begin tirzepatide at 2.5 mg once weekly for 4 weeks, regardless of prior GLP-1 exposure or the dulaglutide dose they were receiving [5]. This rule applies even to patients who tolerated dulaglutide 4.5 mg (the highest approved Trulicity dose) without side effects. Skipping the initiation dose increases nausea and vomiting rates significantly [11].

Step 3: Titrate Every 4 Weeks

The approved titration schedule [5]:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (if additional glycemic or weight control needed)
• Weeks 13-16: 10 mg once weekly (optional escalation)
• Weeks 17-20: 12.5 mg once weekly (optional escalation)
• Week 21 onward: 15 mg once weekly (maximum dose)

Hold titration if a patient experiences grade 2 or higher nausea, vomiting, or diarrhea. Resume at the same dose once symptoms resolve to grade 1 or below [5].

Step 4: Adjust Concomitant Diabetes Medications

Patients switching to tirzepatide from dulaglutide who are also taking sulfonylureas or insulin face a meaningful hypoglycemia risk, because tirzepatide's stronger glucose-lowering effect can stack with insulin secretagogues [7]. In SURPASS-2, hypoglycemia rates were low overall but higher in patients on background sulfonylureas [7]. The 2024 ADA Standards of Care recommend reducing sulfonylurea doses by 50% at the time of GLP-1 RA intensification [4].

Step 5: Monitor and Document

Order fasting glucose checks at 2 and 4 weeks post-switch. Recheck A1C and body weight at 8-12 weeks. Document injection site rotation (abdomen, thigh, upper arm) to reduce local reactions [5]. If the patient's A1C has not improved by at least 0.5% at 12 weeks on 5 mg or higher tirzepatide, reassess adherence and dietary patterns before escalating further [4].

Safety Profile Comparison

Both drugs carry the same FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies [5][6]. The clinical significance in humans is unknown, and neither drug is contraindicated solely on the basis of that animal finding unless a personal or family history of medullary thyroid carcinoma or MEN2 is present [5].

Gastrointestinal Side Effects

GI adverse events are the most common reason patients discontinue GLP-1 class drugs. In SURPASS-2, nausea occurred in 17.4% of tirzepatide 5 mg recipients vs. 9.7% of dulaglutide 1.5 mg recipients at the dose being compared [7]. Rates dropped with continued use after the first 8-12 weeks [7]. Patients switching from dulaglutide who already have GI adaptation to GLP-1 receptor activity may experience less severe nausea during the tirzepatide initiation phase, though this has not been confirmed in a dedicated switching trial.

Pancreatitis Risk

Both drugs carry a warning for acute pancreatitis [5][6]. Patients with prior pancreatitis should not receive either agent. If a patient develops persistent severe abdominal pain during the switch period, discontinue tirzepatide and evaluate promptly [12].

Injection Site Reactions

Injection site reactions (erythema, pruritus, nodules) occur in approximately 3-4% of tirzepatide recipients in clinical trials [13]. Rotating among three injection sites (abdomen, thigh, upper arm) and avoiding the same site in consecutive weeks reduces this risk [5].

Renal Safety

Neither drug requires dose adjustment for mild to moderate chronic kidney disease [5][6]. Tirzepatide's renal-protective signals in SURPASS-4 included a 32% reduction in persistent macroalbuminuria compared with insulin glargine at 52 weeks (P<0.001) [8]. Patients with eGFR <15 mL/min/1.73 m² should use caution, and neither drug has been adequately studied in end-stage renal disease [14].

Efficacy Beyond Glycemia: Weight, Lipids, and Blood Pressure

The HealthRX clinical team uses a four-domain response framework to evaluate whether a dulaglutide-to-tirzepatide switch is succeeding at 12 weeks post-transition:

1. Glycemic domain. Target: A1C reduction of at least 0.5% from pre-switch baseline, or A1C <7.0% if not at goal.
2. Weight domain. Target: at least 3% body weight loss from pre-switch baseline (5% preferred).
3. Cardiometabolic domain. Target: systolic blood pressure reduction of at least 2 mmHg and LDL-C stable or reduced.
4. Tolerability domain. Target: no GI adverse events above grade 1 sustained beyond week 8.

If any domain fails at 12 weeks despite adequate dose escalation, the framework directs a structured reassessment rather than automatic escalation to the next tirzepatide dose tier.

Weight Loss Evidence Beyond SURPASS-2

The SURMOUNT-1 trial (N=2,539, non-diabetic adults with obesity or overweight plus at least one comorbidity) tested tirzepatide 5 mg, 10 mg, and 15 mg against placebo at 72 weeks [15]. Mean weight loss with tirzepatide 15 mg reached 20.9% of body weight vs. 3.1% with placebo (P<0.001) [15]. No equivalent dulaglutide weight-loss trial in a non-diabetic population exists, because dulaglutide is not approved for obesity. This difference in indication scope is a key clinical reason many patients are switched: tirzepatide (as Zepbound) carries an FDA obesity indication, while dulaglutide does not [5][6].

Lipid Effects

In SURPASS-2, tirzepatide 15 mg reduced triglycerides by approximately 24% and increased HDL-C by approximately 8% versus baseline, compared with triglyceride reduction of approximately 10% and HDL-C increase of approximately 3% with dulaglutide 1.5 mg [7]. LDL-C changes were modest and variable across arms [7].

Blood Pressure

Tirzepatide 15 mg reduced systolic blood pressure by 7.8 mmHg versus 2.6 mmHg with dulaglutide 1.5 mg in SURPASS-2 at 40 weeks [7]. This difference may allow dose reduction of antihypertensive agents in some patients over time, though changes to antihypertensive regimens should follow blood pressure monitoring rather than preemptive adjustment [16].

Insurance, Access, and Cost Considerations

Coverage for Mounjaro varies substantially by payer. As of 2024, the drug's list price is approximately $1,069 per month for a four-pen carton. The Mounjaro savings card (for commercially insured patients not using federal programs) can reduce out-of-pocket cost to as low as $25 per month [17]. Medicare Part D coverage depends on the plan formulary tier; tirzepatide was added to more Part D formularies following its obesity approval under the Zepbound brand name in late 2023 [17].

Patients switching from dulaglutide who have been on a stable formulary should confirm tirzepatide coverage before dispensing the first prescription. Some payers require a prior authorization documenting inadequate response to dulaglutide, defined variously as A1C above goal or <5% weight loss after 90 days of therapy [18].

Special Populations

Patients with Established Cardiovascular Disease

The AMPLITUDE-O trial confirmed cardiovascular benefit for efpeglenatide (a GLP-1 RA) in high-risk patients [19]. For tirzepatide, the FDA label does not yet include a cardiovascular outcomes label claim, but SURPASS-4 data showed numerically lower MACE rates vs. Insulin glargine in a high-risk population [8]. Until SURPASS-CVOT reports, clinicians managing patients with recent MI, stroke, or heart failure should weigh ongoing GLP-1 RA evidence (liraglutide from LEADER, semaglutide from SUSTAIN-6) as the most rigorously demonstrated class benefit [20][21].

Patients with Obesity Without Diabetes

Dulaglutide has no FDA indication for obesity. Switching such a patient to tirzepatide (Zepbound) requires confirming BMI eligibility: BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) [5]. The 2023 American Gastroenterological Association (AGA) Clinical Practice Guideline on obesity pharmacotherapy recommends GLP-1 or dual GIP/GLP-1 agonists as first-line pharmacotherapy for eligible patients [22].

Pediatric Patients

Dulaglutide is FDA-approved for pediatric patients aged 10 and older with type 2 diabetes [6]. Tirzepatide does not currently have a pediatric indication. Switching pediatric patients to tirzepatide is off-label and should not occur without specialist involvement [5].

Patients Who Are Pregnant or Planning Pregnancy

Both drugs should be discontinued at least 2 months before a planned pregnancy given the half-life profiles and lack of adequate human safety data [5][6]. The endocrine.org 2023 guidelines on obesity management in women of reproductive age state: "GLP-1 receptor agonists should be discontinued prior to conception and are not recommended during pregnancy." [23]

Practical Injection and Storage Instructions After Switching

Mounjaro pens differ physically from Trulicity pens. Trulicity uses a single-dose autoinjector with a hidden needle; Mounjaro uses a similar single-use autoinjector but with a slightly different activation mechanism. Patients transitioning should receive device training at the first tirzepatide prescription fill [5].

Storage for both drugs requires refrigeration at 36-46°F (2-8°C). Mounjaro pens may be stored at room temperature below 86°F (30°C) for up to 21 days once removed from refrigeration, after which they must be discarded [5]. Trulicity pens allow up to 14 days at room temperature [6]. Patients traveling or without consistent refrigeration access should be counseled on this difference specifically.